JP5992406B2 - 再発した癌患者の治療におけるｉｃａｍ−１に対する抗体の使用 - Google Patents

再発した癌患者の治療におけるｉｃａｍ−１に対する抗体の使用 Download PDF

Info

Publication number
JP5992406B2
JP5992406B2 JP2013519096A JP2013519096A JP5992406B2 JP 5992406 B2 JP5992406 B2 JP 5992406B2 JP 2013519096 A JP2013519096 A JP 2013519096A JP 2013519096 A JP2013519096 A JP 2013519096A JP 5992406 B2 JP5992406 B2 JP 5992406B2
Authority
JP
Japan
Prior art keywords
antibody
cells
icam
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013519096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013539454A (ja
JP2013539454A5 (https=
Inventor
ハンソン、マルクス
フレンデウス、ビョルン
Original Assignee
バイオインヴェント インターナショナル アーベー
バイオインヴェント インターナショナル アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオインヴェント インターナショナル アーベー, バイオインヴェント インターナショナル アーベー filed Critical バイオインヴェント インターナショナル アーベー
Publication of JP2013539454A publication Critical patent/JP2013539454A/ja
Publication of JP2013539454A5 publication Critical patent/JP2013539454A5/ja
Application granted granted Critical
Publication of JP5992406B2 publication Critical patent/JP5992406B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013519096A 2010-07-13 2011-07-13 再発した癌患者の治療におけるｉｃａｍ−１に対する抗体の使用 Expired - Fee Related JP5992406B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1011771.1A GB201011771D0 (en) 2010-07-13 2010-07-13 Biological material and particular uses thereof
GB1011771.1 2010-07-13
PCT/EP2011/061983 WO2012007516A1 (en) 2010-07-13 2011-07-13 Use of antibodies against icam-1 in the treatment of patients with relapsed cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016074000A Division JP2016175906A (ja) 2010-07-13 2016-04-01 再発した癌患者の治療におけるｉｃａｍ−１に対する抗体の使用

Publications (3)

Publication Number Publication Date
JP2013539454A JP2013539454A (ja) 2013-10-24
JP2013539454A5 JP2013539454A5 (https=) 2014-03-20
JP5992406B2 true JP5992406B2 (ja) 2016-09-14

Family

ID=42712312

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013519096A Expired - Fee Related JP5992406B2 (ja) 2010-07-13 2011-07-13 再発した癌患者の治療におけるｉｃａｍ−１に対する抗体の使用
JP2016074000A Pending JP2016175906A (ja) 2010-07-13 2016-04-01 再発した癌患者の治療におけるｉｃａｍ−１に対する抗体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016074000A Pending JP2016175906A (ja) 2010-07-13 2016-04-01 再発した癌患者の治療におけるｉｃａｍ−１に対する抗体の使用

Country Status (10)

Country Link
US (2) US20130189260A1 (https=)
EP (1) EP2593481A1 (https=)
JP (2) JP5992406B2 (https=)
KR (1) KR20130100977A (https=)
CN (1) CN103003308B (https=)
AU (1) AU2011278350B2 (https=)
CA (1) CA2805200A1 (https=)
GB (1) GB201011771D0 (https=)
RU (1) RU2593709C2 (https=)
WO (1) WO2012007516A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
GB2495113A (en) * 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
HK1215174A1 (zh) 2012-11-29 2016-08-19 Bayer Healthcare Llc 針對活化蛋白c的人源化單克隆抗體及其用途
CN104812402A (zh) * 2012-11-29 2015-07-29 拜尔健康护理有限责任公司 针对活化蛋白C (aPC)的单克隆抗体
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
WO2015148971A2 (en) 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
KR101674874B1 (ko) 2014-10-21 2016-11-22 한국원자력의학원 항암제 내성 예측용 바이오마커로서의 ｉｃａｍ－３ 및 이의 용도
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
CN108463121A (zh) * 2016-01-12 2018-08-28 南加利福尼亚大学 长期禁食模仿作为多发性骨髓瘤和其它癌症的膳食治疗的用途
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
CN109949256B (zh) * 2019-01-14 2023-04-07 昆明理工大学 一种基于傅里叶变换的天文图像融合方法
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
JP2023535280A (ja) * 2020-07-20 2023-08-17 エフエヌシーティー バイオテック、インコーポレイテッド 大腸癌転移阻害剤をスクリーニングする方法
CA3187759A1 (en) * 2020-08-04 2022-02-10 Agis Kydonieus Formulations of phosphoinositide 3-kinase inhibitors
KR20230107115A (ko) 2022-01-07 2023-07-14 서울대학교병원 항-icam-1 항체의 단기요법을 이용한 간이식 거부반응의 억제방법
PE20260306A1 (es) 2023-06-12 2026-02-11 Amgen Inc Proteinas de union a receptor de linfotoxina beta agonistas
KR20250179879A (ko) 2024-06-24 2025-12-31 서울대학교병원 항-icam-1 항체를 유효성분으로 포함하는 비알콜성 지방간 또는 비알콜성 지방간염 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA883159B (en) * 1987-05-04 1990-01-31 Dana Farber Cancer Inst Inc Intercellular adhesion molecules and their binding ligands
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CA2717489A1 (en) * 2008-02-29 2009-09-24 Shinshu University Kit for detecting cancer cells metastasizing into sentinel lymph node
GB0903151D0 (en) * 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods

Also Published As

Publication number Publication date
JP2013539454A (ja) 2013-10-24
GB201011771D0 (en) 2010-08-25
CN103003308A (zh) 2013-03-27
AU2011278350A1 (en) 2013-01-10
AU2011278350B2 (en) 2014-03-20
CA2805200A1 (en) 2012-01-19
JP2016175906A (ja) 2016-10-06
CN103003308B (zh) 2016-08-10
KR20130100977A (ko) 2013-09-12
EP2593481A1 (en) 2013-05-22
WO2012007516A1 (en) 2012-01-19
US20130189260A1 (en) 2013-07-25
RU2593709C2 (ru) 2016-08-10
US20160280788A1 (en) 2016-09-29
RU2013105769A (ru) 2014-08-20

Similar Documents

Publication Publication Date Title
JP5992406B2 (ja) 再発した癌患者の治療におけるｉｃａｍ−１に対する抗体の使用
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
US9803013B2 (en) Biological materials and uses thereof
EP3535300A1 (en) Activatable anti-ctla-4 antibodies and uses thereof
AU2018205231A1 (en) Isoform-specific, context-permissive TGFβ1 inhibitors and use thereof
US20250043003A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
AU2018266784C9 (en) LRRC33 inhibitors and use thereof
EP1909819A2 (en) Receptor antagonists for treatment of metastatic bone cancer
KR20090088878A (ko) 신규한 항증식 항체
US20120087916A1 (en) Anti-icam-1 antibody, uses and methods
US20180221482A1 (en) Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patients
CA2997130C (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
EA045239B1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160401

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160817

R150 Certificate of patent or registration of utility model

Ref document number: 5992406

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees